HIV Drug Does Not Impact MS Disease Activity
SEPTEMBER 15, 2016
â€œAlthough the etiology of multiple sclerosis (MS) remains elusive, it is clear that Epstein Barr Virus (EBV) and possibly other viruses have a role in the pathogenesis of MS,â€ researchers started in a poster presentation at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2016) in London, England.
Research has shown that people with the human immunodeficiency virus (HIV) have a significantly lower risk of developing MS. This could be because antiretroviral therapy (ART) inhibits the Human Endogenous Retrovirus â€“ which researchers think could have a role in it as well. However, there is lacking evidence on what happens if HERVs are suppressed.
Monthly MRI screenings, saliva collection for to test EBV shedding, blood sampling, virology, and immunological and inflammatory markers measurement, â€œindicated raltegravir had no significant effect on MS disease activity as measured by either the number or rate of development Gd-enhancing lesions during the treatment phase compared with the baseline phase,â€ the team said.
The drug also did not appear to influence disability or quality-of-life measures.
The researchers identified various reasons why raltegravir didnâ€™t impact MS disease activity. It could have been the type of ART, the need for combination treatment for HIV, the treatment duration, or HERB expression doesnâ€™t play a role in MS once the disease is established.
Also on MD Magazine >>> More News from ECTRIMS 2016 in London